Background: Although Hodgkin's lymphoma (HL) is a curable cancer, current treatment strategies based on risk stratification and response modulation are not precise enough. The predictive power of biological and morphological parameters is controversial, with prognostic models not reaching wide acceptance. Patients and Methods: We analyzed the prognostic relevance of 8 parameters in 85 advancedstage classical HL patients, in order to determine whether tissue-based variables could add prognostic value to standard clinical parameters, thus contributing to better risk stratification at presentation. Results: Univariate analysis confirmed 5 indicators of shorter overall survival (OS): Bcl-2 overexpression; increased CD68+ tumor-associated macrophages (TAM); international prognostic score (IPS) > 2; bulky disease; and total lymph node involvement (TLNI) with regard to neoplastic and inflammatory cells. Apart from TLNI, these parameters influenced lower event-free survival (EFS). Multivariate analysis identified 5 independent factors for OS: Bcl-2 overexpression; increased CD68+ TAM; TLNI; IPS > 2; and bulky disease. Increased CD68+ TAM, IPS > 2, and bulky disease affected the EFS. Utilizing the cumulative score of unfavorable prognostic factors for OS, we designed a prognostic model stratifying patients into 4 risk groups (with 0-1, 2, 3, or 4-5 factors), each with progressively reduced OS (p < 0.001). Conclusion: Our findings support the combination of tissue-based variables with clinical parameters at diagnosis, identifying patients who are at higher risk of poor outcome. 
Pathological Aspects and Immunohistochemistry
Twohematopathologists(MPJandLJ)independentlyreviewedandevaluatedallslides.InallcasesthediagnosisofcHLwasconfirmedbyimmunophenotyping, and classified according to the WHO classification of tumors of the hematopoietic and lymphoid tissues [17] . Immunohistochemicalstainingwasperformedbyapplicationofmonoclonalantibodies for Bcl-2 (124, monoclonal; DakoCytomation, Glostrup, Denmark), survivin (polyclonal; LabVision, Fremont, CA, USA), active caspase 3 (y83-77, monoclonal; Novus Biologicals, Littleton, CO, USA), Ki-67 (MIB1,monoclonal;DakoCytomation),andCD68(PG-M1;DakoCytomation). A peroxidase-labeled detection system was used (LSAB 2, DakoCytomationorUltravisionLPDetectionsystem,LabVision),anda standardantigenretrievalprotocol.Thedeterminationofthenumberand percentageofHRScellsandtumor-associatedmacrophages(TAM)expressingimmunohistochemicalparameterswasperformedusingaLeica ® DMRmicroscope(LeicaMicrosystemsGmbH,Wetzlar,Germany)at10 randomly selected high power fields (×400) within cHL infiltrates. The labelingindexofpositivetumorcellswasdeterminedbythecorrelation betweenpositiveHRSandthetotalnumberofevaluatedHRScells.The percentageofCD68-positive(CD68+)TAMwasdeterminedbycorrelatingCD68+TAMtothetotalnumberofnon-neoplasticcellsinthecHL background. According to previously published data, cutoff values of 50%forBcl-2,survivin,andKi-67,5%foractivecaspase3,and25%for CD68+TAMwereusedforevaluatingimmunohistochemicalresults [11, 13, 18, 19] .
Pathomorphologic Evaluation
ThepathomorphologicfeatureofTLNIbyneoplasticandinflammatory cells(totalinvolvementversusfocalresidualsecondaryfollicles)wasanalyzedaccordingtotheGermanHodgkinStudyGroupcriteria [20] .
Clinical Parameters
Medical records were reviewed for additional clinical and laboratory data: age, gender, Ann Arbor stage, presence or absence of systemic symptoms, bulky disease, hemoglobin, white blood count, lymphocyte count,andserumalbumin.IPSandbulkydiseasewerecalculatedaccordingtotheestablishedcriteria [6, 21] .
Selectedvariableswerechosenonthebasisoftheirprognosticability, capacitytorepresentdifferentaspectsofthedisease,orinteractions.
Treatment
Allpatientsweretreatedwiththesametherapeuticschedule,consisting of6-8cyclesoftheclassicalABVDregimen(doxorubicine,bleomycine, vinblastine, dacarbazine) and additional radiation therapy (RT) to sites of tumor involvement. Patients with treatment failure/relapse received salvage chemotherapy with the DHAP regimen (dexamethasone, cisplatinum, Ara-c). Having completed this combined treatment, patients were assessed for complete remission (CR), partial remission (PR), stable disease(SD),andPD.Treatmentfailurewasdefinedasafailure to achieve CR or PR after the initial therapy, or response (CR/PR) less than 3 months after therapy completion. Relapse was defined as disease reoccurrence if previous CR was achieved at least 3 months after completing treatment, or if the disease progressed in the case of achievedPR.
Introduction
Moderntherapeuticstrategiesresultinremissionaftertheinitial treatment in more than 90% of Hodgkin's lymphoma (HL) patients [1] . However, approximately one third of patients with high-risk prognostic features at presentation die followingrelapseorprogressivedisease(PD) [2] .Inaddition, modern therapy advances in HL are often burdened with treatment-relatedlatesideeffectssuchascardiacfailure,infertility,orsecondarymalignancies [3] .Thus,amoreaccurate prediction of treatment outcome could help to identify patientswhomightrespondlesseffectivelytostandardfirst-line therapy and those who are likely to benefit from reduced treatment [4] .SincethebeginningofHLtreatment,theidentification of prognostic factors and risk-adapted treatment strategieshasbeenamajorissue [5] .Theconventionaltreatmentstrategyhas2complementaryapproaches:i)riskstratification using prognostic models based on adverse clinical parameters such as the International Prognostic Score (IPS) andtheAnnArborclassification;andii)responsemodulation in which therapy is adapted according to positron emission tomography-computed tomography (PET-CT) findings followinginductiontherapy [6] [7] [8] .However,itisdifficulttouse only these treatment strategies since neither is accurate enoughtoprovideatrulypersonalizedtreatmentfortheindividualpatient [1] .ThebiologicalaspectsofHLhavealsobeen exploredinanattempttoidentifyreliableinitialtissue-based variablesasdeterminantsofclinicaloutcome [9] .Histological subtype, phenotypic characteristics of Hodgkin and ReedSternberg(HRS)cells,microenvironmentcelltypecomposition, and increased levels of plasma cytokines/chemokines involved in lymphoma microenvironment formation were relatedtoprognosis [9] [10] [11] [12] [13] [14] [15] .Theirpredictivevaluehasnotyet beenpowerfulenoughtobeincludedintherapeuticdecision making [16] .Theaimofthisstudywastodeterminewhether molecular and pathomorphological parameters could add prognosticvaluetostandardclinicalparametersandcontributetoabetterriskstratificationofHLpatients.Weinvestigated the prognostic impact of molecular (Bcl-2, survivin, active caspase 3, Ki-67, CD68), pathomorphological (total neoplastic and inflammatory lymph node involvement, TLNI), and clinical parameters (IPS and bulky disease) in advancedstageclassicalHL(cHL)patientsatthetimeofthe initialdiagnosis.
Patients and Methods
A retrospective study was performed on a group of 85 patients treated duringtheperiodof1997-2005.Allpatientsfulfilledthefollowingcriteria: initial diagnosis of cHL following a lymph node biopsy before any treatment; representative surgically extirpated, formalin-fixed, paraffinembedded diagnostic lymph node specimen available for histological revisionandfurtherimmunohistochemicalstudies;availableclinicaland laboratorydataonpresentationandfollow-uprecords;negativestatusfor .1 ).Inaddition, TLNIshowedatrendtowardslowerEFS(EFS 5yrs with/without risk factor 48 vs. 66%, respectively; log rank p = 0.087) ( fig. 1) . The factors survivin, active caspase 3, and Ki-67 showed no significant impact on OS (log rank p = 0.065, p = 0.787, and p = 0.187, respectively) and EFS (log rank p=0.153,p=0.677,andp=0319,respectively).
Multivariate Analysis
The multivariate analysis for OS, including all univariately significant risk factors, identified Bcl-2+ > 50%, > 25% CD68+TAM,TLNI,IPS>2,andbulkydiseaseasindependentprognosticfactorsforOS(p=0.026,p=0.042,p=0.004, p=0.0004,andp=0.003,respectively).Inarespectivemodel forEFS,increasedCD68+TAM,IPS>2,andbulkydisease remained significant (p = 0.044, p = 0.009, and p = 0.018, respectively)(table2).
Survival Model
Based on the cumulative score of identified unfavorable prognosticfactorsforOS(2molecular,1morphological,and 
Results
Atpresentation,stageIIB(withbulkymediastinaltumorand/ orextranodaldisease),III,andIVofthediseasewaspresent in 7 (8%), 44 (52%), and 34 (40%) of the patients, respectively.70(82%)patientshadBsymptoms.46(54%)patients weremale,and21(25%)wereolderthan45years(meanage 35.43±13.5years;range16-68years).43(51%)patientshad ahighIPSscore(>2).Atinitialdiagnosis,bulkydiseasewas confirmedin34(40%)patients.Accordingtohistopathological tumor type, 78% were classified as nodular sclerosis subtype, 14% mixed cellularity, 5% lymphocyte-rich cHL, and3%lymphocytedepletion(table1).Bcl-2,survivin,active caspase-3, and Ki-67 were expressed in HRS cells of 64 fig.1 ). The5-yearOSwasprogressivelyworseaccordingtotherisk groups:inlowriskpatients,itwas100%,intermediate78%, high 45%, and very high 0% (chi square = 42.13, p < 0.001) ( fig.2) .
Discussion
Theresultsofourstudyconfirmed5independentindicators affectingOSinadvancedstageHL.Theseareoverexpression ofBcl-2(>50%);increasednumberofCD68+TAM(>25%); TLNI;highIPS(>2);andbulkydisease.Ofthese,increased numberofCD68+TAM,IPS>2,andbulkydiseasealsoaffectedEFS.Combiningtheidentifiedunfavorableprognostic factorsforOS(Bcl-2;CD68;TLNI;IPS;andbulkydisease), wedesignedaprognosticmodelwhichstratifiespatientsinto 4riskgroups.
Certainindicatorssuggestthatpooreroutcomemightdependonaspecificmolecularmechanisminfluencingtherapy response [22, 23] .TheroleofBcl-2hasbeenwidelydebated in the literature without concordant results. Several reports indicatedthatitsoverexpressioninHRScellsisapredictorof pooroutcome [24, 25] .Garciaetal. [11] triedtoincorporate biologicvariablesintothestandardclinicalprognosticscoring system. Shorter survival was directly connected with Bcl-2 overexpressionandothervariablessuchasBcl-Xl,p53,Bax, MIB1,andtheapoptoticindex.Also,Supetal. [26] demonstrated that Bcl-2 but not p53 and p21 was an independent prognosticfactorforsurvival.Whenclinicalparameters(age ≥45andstageIIIorIV)wereadded,thescoringsystemstratifiedpatientsinto3riskgroups(with0,1,or2-3riskfactors) and progressively worse OS and failure-free survival (FFS). More recently, Sanches-Espiridon et al. [27] identified Bcl-2 tobeoneofthebestpredictorgenesinadvancedstagecHL patients.Bcl-2isintegratedintoagenepredictionmodel(including functional pathways: cell cycle, apoptosis, macrophage activation, and interferon regulatory factor 4) which stratifiedlow-andhigh-riskpatientswithdifferentFFSrates. However, other reports show that Bcl-2 is not significantly relatedtooutcome [9, 28, 29] .Inourstudy,patientswithBcl-2 overexpressionhadaworseoutcomeunivariatelyaswellasin amultivariatemodeladjustedforotherrelevantriskfactors. Anotheradverseprognosticfactoristheincreasednumber ofTAM,describedbothinsolidtumorsandB-cellmalignancies [30] [31] [32] .Inaddition,severalstudiesrevealedaprognostic relevanceinHL [33] [34] [35] .However,manyquestionsregarding phenotype,chemotaxis,andtheirinfluenceontreatmentresistanceinHLremainunanswered.Steidletal. [13] showed that an elevated number of CD68+ TAM predicts poor outcome in advanced stage patients, while their absence in limitedstagediseasecorrelatedwithtotallong-termdiseasespecific survival. Additionally, Kamper et al. [36] indicated that high expression of the macrophage/monocyte-related antigens CD68 and CD163 was significantly correlated with decreasedOSandEFS,withincreasedCD68beinganinde-pendentfactorforsurvival.Geneexpressionprofilingstudies also established the significance of TAM in relation to primarytreatmentfailure [13, 37] .Ontheotherhand,Azambuja etal. [38] couldnotverifytherelationshipbetweenthenumber of CD68+ and CD163+ macrophages with clinical outcome.Inourstudy,wewereabletodemonstratethatanincreasednumberofTAMhadaworseprognosiswithrespect toOSandEFS.Furthermore,theCoxmultivariatemodelrevealedthattheprognosticimpactwasindependentfromother relevantfactorsforOSandEFS. TAM are part of the nursing cells in the tumor microenvironment. It is implicated that the unique local microenvironment effect (also referred to as the 'premetastatic niche') might be responsible for homing of circulating HL cellstocontiguouslymphnodesearlyinthecourseofdisease, determiningthepatternofmetastaticdissemination [39, 40] . CelllinestudiesshowedthatclonotypicBcellsappearstobe responsibleforthemaintenanceandgenerationofHRScells [41] .Also,therearefindingsrevealinghighlevelsofcirculatingclonotypicBcellsinstageIVHLaswellasinearly-stage diseaseinmostpatients [41] .
InthestudybyWasielewskietal. [20] involving965nodu-lar sclerosis subtype cHL patients of all stages, the authors foundthatTLNIwithtumorandreactivecellswaspresentin 79% cases, without influencing survival. In our study, 31 (36%) cases with neoplastic and inflammatory TLNI (26 of them with nodular sclerosis) had worse OS both in the univariateandthemultivariatemodeladjustedforotherrelevant riskfactors.Additionallytherewasanon-significanttrendtowards lower EFS in this group. The interaction between tumorstemcellsandtheformationandanatomicalorganization of the specialized environment which supports them is stillunderinvestigation [42] .WhetherTLNIrepresentsapart ofthisprocess,possiblyinfluencingtheclinicobiologicalvariabilityofthedisease,isyettobeclarified.
Our research also confirmed the predictive value of the clinicalfactorsIPSandbulkydisease,usuallyconsideredimportant in HL prognosis. We developed a prognostic model for OS, which integrates both clinical and tissue-based variables, in order to stratify advanced stage cHL patients into riskgroups.ThekeyparametersforstratificationwereBcl-2 positivityin>50%ofHRScells,>25%CD68+TAM,neoplastic and inflammatory TLNI, IPS > 2, and bulky disease. Basedonthecumulativescoreoftheseriskfactors,patients werestratifiedinto4groups(low0-1,intermediate2,high3, veryhigh4-5risk),eachwithprogressivelyreducedOS.Accordingtoourfindings,patientshaving2ormoreriskfactors atthetimeoftheinitialdiagnosisareathigherriskofapoor outcome.Thismodel,whichenablespreciseriskstratification atpresentation,maybeusedtoguideanindividualtreatment approach,althoughitspredictivevalueneedstobeconfirmed instudieswithlargernumbersofpatients.
